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Hepatocellular carcinoma (HCC) accounts for approximately 80% of liver cancers, the
third most frequent cause of cancer mortality. The most prevalent risk factors for HCC are
infections by hepatitis B or hepatitis C virus. Findings suggest that hepatitis virus-related
HCCmight be a cancer in which LINE-1 retrotransposon, often termed L1, activity plays a
potential role. Firstly, hepatitis viruses can suppress host defense factors that also control
L1 mobilization. Secondly, many recent studies also have indicated that hypomethylation
of L1 affects the prognosis of HCC patients. Thirdly, endogenous L1 retrotransposition
was demonstrated to activate oncogenic pathways in HCC. Fourthly, several L1 chimeric
transcripts with host or viral genes are found in hepatitis virus-related HCC. Such lines
of evidence suggest a linkage between L1 retrotransposons and hepatitis virus-related
HCC. Here, I briefly summarize current understandings of the association between
hepatitis virus-related HCC and L1. Then, I discuss potential mechanisms of how
hepatitis viruses drive the development of HCC via L1 retrotransposons. An increased
understanding of the contribution of L1 to hepatitis virus-related HCCmay provide unique
insights related to the development of novel therapeutics for this disease.
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INTRODUCTION
Liver cancer, 80% of which is hepatocellular carcinoma (HCC), accounts for 9% of all cancer deaths
worldwide (Jemal et al., 2011; Tateishi and Omata, 2012). The major causative agents of HCC are
hepatitis viruses, such as hepatitis B virus (HBV) or hepatitis C virus (HCV) (Jemal et al., 2011;
Tateishi and Omata, 2012). HBV belongs to theHepadnaviridae family, which has a relaxed circular
DNA (rcDNA) as a viral genome (Beck and Nassal, 2007; Nguyen et al., 2008). HCV belongs to the
Flaviviridae family, which has a nonsegmented, positive-stranded RNA as a viral genome (Hijikata
et al., 1991; Grakoui et al., 1993; Aly et al., 2012). Both viruses cause chronic infections, with
approximately 350 and 170million people worldwide affected by chronic HBV andHCV infections,
respectively (Parkin, 2006; Aly et al., 2012). It is now clear that chronic HBV and HCV infections
play critical roles in the development of HCC (Jemal et al., 2011; Forner et al., 2012; Tateishi and
Omata, 2012). However, the precise mechanisms of hepatocarcinogenesis in chronic hepatitis virus
infections are still unclear.
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Long interspersed nuclear element-1 (LINE-1 or L1)
retrotransposons are genetic elements that constitute
approximately 17% of the human genome (Lander et al., 2001).
Because most L1s are 5′ truncated, most of them are defective,
while 80–100 copies are still retrotransposition-competent and
utilize a “copy-and-paste” mechanism to retrotranspose to new
genomic loci (Brouha et al., 2003; Beck et al., 2010). Aberrantly
expressed or dysregulated L1s are considered a major source of
endogenous mutagenesis in humans (Levin and Moran, 2011;
Burns and Boeke, 2012). L1 retrotransposition occurs in germ
cells, pluripotent stem cells, at early stages of human embryonic
development (van den Hurk et al., 2007; Beck et al., 2011; Levin
and Moran, 2011; Klawitter et al., 2016) and in somatic cells,
such as neuronal progenitor cells or cancer cells (Muotri et al.,
2005; Iskow et al., 2010). Many epidemiological studies suggest a
linkage between L1 and cancers (Shukla et al., 2013; Rodic´ et al.,
2014; Harada et al., 2015). However, in most cases, it is unclear
whether L1s are activated in normal cells before clonal expansion
or in cancer cells at the later stage of carcinogenesis (Goodier,
2014).
Among cancers, hepatitis virus-related HCC is considered to
be a cancer in which L1 might be involved (Shukla et al., 2013).
Firstly, by far the majority of L1 de novo insertions detected
in cancer tissues has been found in cancers of epithelial origin
(Goodier, 2014). Secondly, HBV and HCV have a potential
to suppress host defense mechanisms that can also control L1
retrotransposition (Gale and Foy, 2005; Chang et al., 2012; Yu
et al., 2015). Thirdly, endogenous L1 retrotransposition was
demonstrated to activate oncogenic pathways in HCC. Fourthly,
several L1 chimeric transcripts with host or viral genes are
found in hepatitis virus-related HCC (Lau et al., 2014). Here,
I will summarize potential linkages between hepatitis virus-
related HCC and L1s. Firstly, I will review how HBV could
affect L1 retrotransposon activity. I will then introduce current
understandings of the relationship between HCV and L1. Finally,
I will discuss possible L1-mediated mechanisms that may induce
HCC. Understandings of possible links between virus-related
HCC and L1 may open a new avenue for the development of
novel therapeutics for this disease.
A POTENTIAL LINK BETWEEN HBV AND
L1 IN HCC
The 3.2-kb HBV genome encodes four, partly overlapping open
reading frames (ORFs): preC/C (core and Hepatitis B e-Antigen
[HBeAg]), P (viral polymerase), preS/S (Hepatitis B surface
Antigen [HBsAg]) and X (non-structural protein [HBx]) genes
(Figure 1A). In the nucleus, the genome is converted into
covalently closed circular DNA (cccDNA). From this cccDNA, all
viral RNAs, including pregenomic RNA (pgRNA) as a replication
intermediate and viral mRNAs, are transcribed. Viral proteins
such as core and polymerase proteins and pgRNAs are assembled
into the nucleocapsid within the cytoplasm. In the nucleocapsid,
pgRNA is reverse transcribed into rcDNA. All these HBV-
related nucleic acids have the potential to trigger innate immune
responses in infected cells (Ait-Goughoulte et al., 2010). If
these immune responses cannot clear HBV, the virus establishes
a chronic infection, which is known to increase the risk of
developing liver cirrhosis and HCC (Gonzalez and Keeffe, 2011).
Type I interferons (IFNs) play a major role in anti-viral
immunity (Katze et al., 2002). Association of IFNs with IFN
receptors activates JAK1 and signal transducer and activator
of transcription 1/2 (STAT1/2). Then, these proteins interact
with interferon regulatory factor 9 (IRF9) and form a potent
transcription factor, upregulating the expression of several
hundreds of IFN-stimulated genes (ISGs). These ISGs suppress
viral replication and spread through various mechanisms
described elsewhere (Katze et al., 2002). IFN is used to control
HBV replication, indicating that IFN is a restriction factor
(Dienstag, 2008). For example, tetherin, an IFN-inducible
transmembrane protein, inhibits HBV virion secretion (Yan
et al., 2015). Zinc finger antiviral protein (ZAP) is upregulated
in IFN-treated cells and restricts HBV replication through
downregulation of pgRNA (Mao et al., 2013). On the other
hand, HBV has a variety of strategies to counteract IFN signaling
(Figure 1A). HBsAg, HBeAg and HBV virions inhibit Toll-like
receptor (TLR)-mediated antiviral responses (Visvanathan et al.,
2007; Wu et al., 2009; Vincent et al., 2011; Woltman et al., 2011).
HBV polymerase suppresses IRF3 activation by interacting
with the host RNA helicase, DDX3 (Wang and Ryu, 2010; Yu
et al., 2010). HBV polymerase also disrupts ubiquitination of
the stimulator of interferon genes (STING) and blocks innate
immune responses against cytoplasmic DNA (Liu et al., 2015).
Expression of HBx protein inhibits virus-induced expression of
the IFN gene by promoting the decay of mitochondrial antiviral
signaling protein (MAVS) (Wei et al., 2010; Kumar et al.,
2011). Furthermore, HBV abrogates IFN signal transduction
by impairing either STAT1 nuclear import or phosphorylation
(Christen et al., 2006, 2007; Lütgehetmann et al., 2011). All the
listed mechanisms that suppress IFN signaling could also activate
L1 retrotransposon, because IFN has been shown to inhibit the
expression and retrotransposition of L1 (Yu et al., 2015). The
mechanisms underlying the inhibitory effect of IFN on L1 remain
unclear. However, MOV10 is an attractive candidate to mediate
this inhibitory effect, because MOV10 is an IFN-inducible gene
and suppresses L1 retrotransposition (Schoggins et al., 2011;
Goodier et al., 2012). Collectively, immune suppression by
HBV may activate the expression and retrotransposition of L1
elements.
In addition, HBV may also modulate L1 expression
epigenetically. L1 retrotransposition activity is usually suppressed
in most somatic cells by host DNA methyltransferase-mediated
DNAmethylation of its promoter (Ishizu et al., 2012; Castro-Diaz
et al., 2014). In cancer cells, global DNA hypomethylation occurs
at various genomic loci including those containing DNA repeats
and/or retrotransposons (Ehrlich, 2002; Hatziapostolou and
Iliopoulos, 2011). Many studies have reported hypomethylation
of the L1 loci in HCC and HBV infection (Shitani et al., 2012;
Zhang C. et al., 2013; Gao et al., 2014; Zhu et al., 2014). In
particular, L1 hypomethylation is likely to be linked to poor
outcomes of HCC (Gao et al., 2014; Zhu et al., 2014). Given
global hypomethylation occurs in the host genome (including
the L1 loci) during HBV infection, this may upregulate L1
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FIGURE 1 | Genomic structure of hepatitis viruses and immune invasion by their proteins. (A) HBV. Black arrows indicate HBV genomic rcDNA (from 5′ to
3′). Blue and red arrows indicate structural and non-structural proteins, respectively. Host genes in immune responses targeted by HBV proteins are shown. (B) HCV.
Black arrow indicates HCV genomic RNA (from 5′ to 3′). Blue and red boxes indicate structural and non-structural proteins, respectively. Host genes in immune
responses targeted by HCV proteins are shown.
expression, potentially removing an obstacle to L1 transposition
in liver cells. In addition, some chimeric transcripts, such
as HBx-L1, are detected in HCC and associated with a poor
prognosis, further supporting the link between HBV-related
HCC and L1 (Lau et al., 2014).
A POTENTIAL LINK BETWEEN HCV AND
L1 IN HCC
The 9.6-kb HCV genome contains a single ORF, encoding a
polyprotein precursor of approximately 3000 amino acids. The
polyprotein is cleaved by host and viral proteases, producing
structural (core, E1 and E2) and non-structural (P7, NS2,
NS3, NS4A, NS4B, NS5A and NS5B) proteins (Figure 1B). The
replication of HCV starts with the synthesis of a full-length,
negative-stranded RNA intermediate, which in turn works as
a template for the de novo production of positive-stranded
genomic RNA. Thus, HCV replicates without a known DNA
intermediate stage. HCV genomic RNA is highly structured and
contains double-stranded regions in various portions (Tuplin
et al., 2002; Zhang S. et al., 2013). Double-stranded RNAs
(dsRNAs) are also generated during the replication cycle of HCV.
Such dsRNAs are potent inducers of innate immune responses,
mainly through TLR3 and retinoic acid inducible gene-I (RIG-I)
signal pathways (Li et al., 2012). However, the immune responses
induced by HCV are not strong enough to eradicate the virus
(Battaglia and Hagmeyer, 2000).
Although it is thought that non-retroviral RNA viruses
are not integrated into host genomic DNA, we and others
have demonstrated that they do become integrated into the
host genome via host retrotransposon machineries (Geuking
et al., 2009; Horie et al., 2010). Likewise, HCV cDNA is
reportedly detected in patients infected with HCV (Zemer
et al., 2008). Because the involvement of HIV was ruled out
in all the HCV cDNA-positive patients, it is hypothesized that
host retrotransposons might be involved (Zemer et al., 2008).
However, the retrotransposons responsible for this phenomenon
remain unidentified and the involvement of retroviruses other
than HIV is not ruled out. Because the 3’UTR of HCV is not
polyadenylated, the contribution of L1, whose substrates are
usually polyadenylated, to this phenomenon seems to be unlikely.
However, several reports propose alternative retrotransposition
mechanisms by L1, termed internal priming or twin priming,
where a poly-A tail is not required to prime reverse transcription
(Ostertag and Kazazian, 2001; Srikanta et al., 2009). These
alternative mechanisms may explain how HCV RNA could be
reverse transcribed by L1, despite lacking a poly-A tail. It is also
unknownwhetherHCV cDNA is integrated into the host genome
or exists as extrachromosomal DNA. A recent report showed that
fragments homologous to HCV genes are present in the rabbit
and hare genomes, whichmight suggest the possibility that cDNA
of an HCV ancestor has been integrated into the host genome
(Silva et al., 2012). These observations imply that some linkages
between HCV and retrotransposon activity might exist.
Most HCV-infected patients develop a chronic infection,
suggesting that HCV has developed successful strategies to
evade host immune responses (Gale and Foy, 2005) (Figure 1B).
For instance, the HCV NS3/4A protease cleaves the Toll/IL-
1 receptor domain-containing adaptor inducing IFN-β (TRIF)
adaptor protein and MAVS to impair TLR3 and retinoic acid-
inducible gene-I (RIG-I) signaling pathways, respectively (Foy
et al., 2005; Li K. et al., 2005; Li X.-D. et al., 2005). NS5A
and E2 proteins suppress the signaling of the interferon-
dependent induced protein kinase R (PKR), a key molecule
in the innate immune system (Gale et al., 1997; Taylor et al.,
1999). The interferon sensitivity-determining region (ISDR) in
the NS5A protein interacts with the death domain of myeloid
differentiation primary response 88 protein (MyD88), a major
adaptor protein in TLR signaling, and impairs its signaling (Abe
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et al., 2007). All these mechanisms that suppress IFN responses
against HCV could in turn activate retrotransposons, such as
L1, in infected cells, because IFN and IFN-inducible genes, such
as MOV10, are shown to suppress retrotransposition of L1s as
described above (Schoggins et al., 2011; Goodier et al., 2012; Yu
et al., 2015).
The HCV core protein has an oncogenic potential (Moriya
et al., 1998; Shimotohno, 2000). One mechanism put forward
for this is that the core protein modulates host gene expression
pathways which may activate oncogene expression (Shrivastava
et al., 1998; Marusawa et al., 1999; Shimotohno, 2000; Watashi
et al., 2001; Ray et al., 2002). In addition to the core protein, NS5A
protein also stimulates NF-κB signaling (Ray et al., 1995; Gong
et al., 2001; Park et al., 2002; Waris et al., 2003). Similarly, HCV
proteins may stimulate the expression of L1 retrotransposons.
Indeed, the infectious HCV virion reportedly activates HIV
long terminal repeats (LTR) and upregulates gene transcription
(Sengupta et al., 2013). However, studies investigating whether
HCV proteins have the potential to stimulate L1 expression
and/or retrotransposition have not been reported so far.
POSSIBLE MECHANISMS OF L1
INVOLVEMENT IN HCC DEVELOPMENT
Although a definitive role for L1 activity in contributing to HCC
etiology has not been established thus far, investigating a possible
link between L1 activation and the development of HCC would
be of considerable interest for a number of reasons (Figure 2).
Firstly, L1s, when aberrantly expressed or dysregulated, can
be major sources of endogenous mutagenesis in humans as
described above (Levin and Moran, 2011; Burns and Boeke,
2012). Any potential disruption of tumor suppressor genes by
L1 retrotransposition could contribute to the development of
HCC. Indeed, L1 was shown to be a crucial source of mutations
that can reduce the tumor-suppressive capacity of somatic cells
(Shukla et al., 2013). A subset of L1 de novo insertions identified
in cancer tissue occurred at genes commonly mutated in cancer
(Lee et al., 2012). Secondly, L1 de novo insertions can affect the
expression of nearby genes and the genes in which they inserted
(Lee et al., 2012; Shukla et al., 2013). Intragenic L1 insertions
usually coincide with reduced gene expression (Lee et al., 2012).
For example, L1 insertions into the tumor suppressor mutated in
colorectal cancer (MCC) gene coincides with its downregulation
(Shukla et al., 2013). MCC is expressed in liver and suppresses the
oncogenic β-catenin/Wnt signaling pathway frequently activated
in HCC (Fukuyama et al., 2008). If an L1 insertion occurs close
to an oncogene, L1 could enhance oncogene expression, resulting
in the development of HCC. For example, the telomerase reverse
transcriptase (TERT) gene is one of the most common genes
associated with L1 de novo insertion (Ding et al., 2012; Lau
et al., 2014). Since aberrant expression of TERT is associated
with tumor development, L1 insertion near the TERT locus may
have a role in carcinogenesis (Cohen et al., 2007; Nault et al.,
2015). L1 insertion at the transcriptional repressor suppression
of tumorigenicity 18 (ST18) gene activates its expression (Shukla
et al., 2013). ST18 is a candidate oncogene in liver, because the
expression of ST18 is upregulated in several liver cancer cells
and in tumors in a mouse-model for inflammation-driven HCC
(Shukla et al., 2013). Thirdly, L1 provides sites that could lead
to genomic rearrangements (Burwinkel and Kilimann, 1998).
Such genomic rearrangements contribute to genomic instability
(Burwinkel and Kilimann, 1998; Ehrlich, 2002). Fourthly, L1
retrotransposition could contribute to new splice donor or
acceptor sites, which could alter the host transcriptome and
might enhance HCC progression (Singer et al., 2010). Lastly, L1
retrotransposition occasionally creates new chimeric transcripts,
whichmight enhance the progression toHCC. An example of this
mechanism is the L1-MET transcript, a chimeric transcript that
consists of the c-MET oncogene and an intronic L1 sequences
(Zhu et al., 2014). The expression of L1-MET has been shown
to be correlated with that of c-MET (Zhu et al., 2014). Because
L1-MET is associated with poor prognosis in cancer (Wolff et al.,
2010; Hur et al., 2014), L1-MET might be associated with a poor
prognosis for HCC via the activation of c-MET signaling (Zhu
et al., 2014).
Taken together, I conclude two potential roles for L1 elements
in the development of hepatitis virus-related HCC. The first
relates to a chimeric transcript specific to HBV-related HCC,
HBx-L1, which can be detected in more than 20% of HBV-related
HCC and correlates with a poor outcome (Lau et al., 2014).
The promoter of the HBx gene transcribes HBx-L1 from the
locus that is normally silent in the genome. Knockdown of HBx-
L1 reduces migratory and invasive properties of HBV-positive
HCC cells. HBx-L1 overexpression confers growth advantage and
promotes cell migration and invasion regardless of its chimeric
protein-coding potential, suggesting that HBx-L1 is a long non-
coding RNA that promotes HCC phenotypes. Furthermore, it has
been shown that HBx-L1 affects β-catenin/Wnt signaling, amajor
pathway in the oncogenesis of HBV-related HCC, confirming
its role in HCC (Whittaker et al., 2010; Lau et al., 2014). In
addition to this, I hypothesize the other possible role of L1 as a
potent inducer of the expression of cytidine deaminases, such as
activation-induced cytidine deaminase (AID) and apolipoprotein
B mRNA editing enzyme, catalytic polypeptide 3 (APOBEC3).
Since transgenic mice expressing AID genes invariably induce
tumors, this suggests that cytidine deaminases may have a
carcinogenic potential (Okazaki et al., 2003; Takai et al., 2009).
APOBEC3 is a protein family of seven proteins in human:
APOBEC3A, B, C, DE, F, G, and H (Schumann et al., 2010; Vieira
and Soares, 2013). Members of the APOBEC3 protein family
restrict replication of not only retroviruses such as HIV, but
also retrotransposons, HBV and HCV (Harris and Liddament,
2004; Vieira and Soares, 2013). Among APOBEC3 proteins,
APOBEC3G seems to have a major role in HIV restriction
(Chaipan et al., 2013; Vieira and Soares, 2013). APOBEC3G also
has the restriction activity against LTR retrotransposons in the
mouse genome (Esnault et al., 2005; Schumacher et al., 2008).
All members of the human APOBEC3 protein family of cytidine
deaminases restrict L1 retrotransposition with APOBEC3A, B, C
and F having the strongest inhibitory effect (Muckenfuss et al.,
2006; Kinomoto et al., 2007). For HBV and HCV, APOBEC3G
is a major restriction factor (Vartanian et al., 2010; Peng et al.,
2011; Kitamura et al., 2013). HBV and HCV somehow stimulate
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FIGURE 2 | The possible involvement of L1 in the development of hepatitis virus-related HCC. HBV infection leads to global hypomethylation of genomic
DNA and suppresses host immune responses. HBV also integrates its sequence into the host genome, altering the host transcriptome. HCV can activate transcription
of host genes and suppress host immune responses. Furthermore, HCV cDNA might be formed in HCV-infected cells. I hypothesize that these changes could be
associated with L1 retrotransposition. L1 activation may lead to the mutagenesis of host tumor suppressor genes, the activation of oncogenes, host genomic
instability, and the production of new chimeric transcripts or activation of cytidine deaminases, all of which contribute to the development of HCC.
the expression of cytidine deaminases (Vartanian et al., 2010).
Furthermore, L1 activation reportedly increases the expression
of the mouse APOBEC3 gene in mouse embryonic fibroblasts
(Yu et al., 2015). Taken together, hepatitis viruses, directly
and/or maybe indirectly via L1 activation, induce the expression
of cytidine deaminases, which may hyperedit host genomes,
resulting in the accumulation of deleterious mutations in the
genome and the development of HCC (Okazaki et al., 2003; Takai
et al., 2009; Vartanian et al., 2010).
CONCLUSION AND PERSPECTIVE
Presented lines of evidence suggest potential links between
hepatitis virus infection and L1 retrotransposon activity.
Especially, L1 hypomethylation or some L1 chimeric transcripts
are associated with poor prognosis of HCC, suggesting that it can
have a significant effect on HCC phenotypes and supporting the
idea that HCC is a cancer in which L1 plays a role. However,
knowledge of how L1 activation by chronic hepatitis virus
infection enhances the development of HCC is still limiting.
Further accumulation of examples of recurrent L1 insertion
sites in the host genome or recurrent chimeric transcripts
specific to hepatitis virus-related HCC will be promising ways
to understand L1 involvement in HCC etiology. Single cell
analyses of L1 retrotransposition events and expression in
tumor cells and surrounding normal cells may enhance these
processes. Understanding the potential roles of L1 in HCC may
open avenues to developing novel therapeutics, such as RNA
interference against HCC-specific L1 chimeric transcripts.
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